Cabergoline
Alternative Names: Cabaser; CG 101; Dostinex; FCE 21336; PNU 142799Latest Information Update: 27 Apr 2024
At a glance
- Originator Pfizer
- Developer Kissei Pharmaceutical
- Class Antiparkinsonians; Ergolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Galactorrhoea; Hyperprolactinaemia; Parkinson's disease
- Discontinued Breast cancer; Pituitary cancer; Restless legs syndrome